Latest Stocks: EXACT Sciences Co. (EXAS) Downgraded by Vetr Inc.

Latest Stocks: EXACT Sciences Co. (EXAS) Downgraded by Vetr Inc.

Vetr cut shares of EXACT Sciences Co. (NASDAQ:EXAS) from a strong-buy rating to a hold rating in a research note published on Wednesday. Vetr currently has $35.91 target price on the medical research company’s stock.

A number of other equities analysts have also weighed in on EXAS. Craig Hallum set a $26.00 price target on EXACT Sciences and gave the company a buy rating in a research report on Tuesday, January 31st. Benchmark Co. upgraded EXACT Sciences from a hold rating to a buy rating and increased their price target for the company from $17.00 to $27.00 in a research report on Tuesday, February 21st. Roth Capital upgraded EXACT Sciences from a neutral rating to a buy rating and increased their price target for the company from $15.00 to $26.00 in a research report on Wednesday, February 22nd. Canaccord Genuity reiterated a buy rating and issued a $24.00 price target (down previously from $27.00) on shares of EXACT Sciences in a research report on Wednesday, February 22nd. Finally, Zacks Investment Research lowered EXACT Sciences from a buy rating to a hold rating in a research report on Friday, February 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $31.93.

Shares of EXACT Sciences (NASDAQ EXAS) opened at 37.07 on Wednesday. EXACT Sciences has a 52-week low of $6.90 and a 52-week high of $38.92. The company’s 50-day moving average price is $31.11 and its 200-day moving average price is $21.75. The stock’s market cap is $4.12 billion.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Thursday, April 27th. The medical research company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.09. EXACT Sciences had a negative return on equity of 43.48% and a negative net margin of 72.26%. The business had revenue of $48.36 million during the quarter, compared to analysts’ expectations of $37.38 million. During the same quarter last year, the business posted ($0.49) earnings per share. The company’s quarterly revenue was up 225.9% on a year-over-year basis. Analysts expect that EXACT Sciences will post ($1.35) earnings per share for the current year.

In other EXACT Sciences news, insider Kevin T. Conroy sold 12,059 shares of the firm’s stock in a transaction dated Monday, March 13th. The stock was sold at an average price of $21.16, for a total transaction of $255,168.44. Following the completion of the sale, the insider now directly owns 817,239 shares in the company, valued at approximately $17,292,777.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP D Scott Coward sold 1,543 shares of the firm’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $23.74, for a total value of $36,630.82. Following the sale, the senior vice president now owns 55,478 shares of the company’s stock, valued at $1,317,047.72. The disclosure for this sale can be found here. Insiders have sold a total of 21,159 shares of company stock valued at $451,705 over the last 90 days. Corporate insiders own 5.60% of the company’s stock. A number of large investors have recently made changes to their positions in the company. Cantab Capital Partners LLP raised its stake in shares of EXACT Sciences by 5,352.2% in the fourth quarter. Cantab Capital Partners LLP now owns 7,524 shares of the medical research company’s stock worth $101,000 after buying an additional 7,386 shares during the last quarter. Massmutual Trust Co. FSB ADV acquired a new stake in shares of EXACT Sciences during the fourth quarter worth approximately $134,000. Intellectus Partners LLC acquired a new stake in shares of EXACT Sciences during the fourth quarter worth approximately $134,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of EXACT Sciences during the fourth quarter worth approximately $192,000. Finally, Botty Investors LLC acquired a new stake in shares of EXACT Sciences during the first quarter worth approximately $200,000. Hedge funds and other institutional investors own 86.54% of the company’s stock.

To view Vetr’s full report, visit Vetr’s official website.

Related posts

Leave a Comment